Randomized, double-blind, sham-controlled trial of an intraoral photobiomodulation device for oral mucositis due to radiotherapy for head and neck cancer

This randomized, double-blind, sham-controlled trial demonstrates that daily intraoral LED-based photobiomodulation is a safe and effective intervention that significantly reduces the incidence and severity of oral mucositis and associated complications in head and neck cancer patients undergoing radiotherapy.

The Gist

Imagine you are building a house (your body) and you need to use a very powerful, precise laser (radiation therapy) to remove a dangerous termite infestation (cancer) in the walls. The laser is amazing at killing the termites, but it's a bit like a sledgehammer: while it targets the termites, it inevitably smashes up the drywall and paint around them. In the mouth, this "smashed drywall" is called Oral Mucositis. It's essentially severe, painful sores that make eating, swallowing, and even talking feel like chewing on broken glass.

For many head and neck cancer patients, this pain is so bad they have to stop treatment, lose weight, or get a feeding tube. Doctors have known for a while that a specific type of light therapy (called Photobiomodulation or PBM) acts like a "healing flashlight" that soothes the tissue and helps it repair itself. But using these lights has been like trying to paint a whole room with a tiny, handheld paintbrush: it's slow, tiring for the staff, and hard to do perfectly every single day.

The Big Experiment

This paper describes a major scientific experiment designed to test a new, high-tech solution: a smart mouthguard filled with tiny LED lights.

Think of this device as a "solar-powered healing helmet" for your mouth. Instead of a doctor holding a light wand for 20 minutes, the patient just bites down on this custom mouthpiece for 10 minutes before their radiation treatment. The mouthpiece has little light pipes that shine healing light onto every sore spot inside the mouth, automatically and evenly.

How They Tested It

The researchers set up a "blind taste test" scenario, but for medicine:

• The Players: 85 patients with head and neck cancer.
• The Teams: They were split into two groups.
  • Team Light: Got the real mouthguard with the healing LED lights.
  • Team Shadow: Got an identical-looking mouthguard that looked and felt the same but had the lights turned off (a "sham" or fake treatment).
• The Rules: Neither the patients nor the doctors knew who was getting the real light or the fake light. This ensures the results are fair and not just in people's heads.

What Happened?

The results were like finding a secret shield that protected the house walls from the laser damage.

1. Fewer Severe Sores: The group with the real light had significantly fewer cases of the worst kind of mouth sores. Imagine if 57 out of 100 people in the fake group got severe sores, but only 36 out of 100 in the real group did. That's a huge difference.
2. Less Pain: People in the light group reported much less pain in their mouths and throats. It was like the difference between walking on a beach with sharp shells versus walking on soft sand.
3. Better Taste: Radiation often ruins your sense of taste (making food taste like metal or nothing at all). The light group kept their taste buds working much better than the fake group.
4. No Feeding Tubes Needed: Because the light group could still eat and swallow, far fewer of them needed to have a tube surgically inserted into their stomach to get food.
5. Safety: The "healing helmet" was completely safe. No one got hurt by the light, and almost everyone finished every single session.

The Catch (The "Subgroup" Surprise)

The study found something interesting: The light worked best for patients who didn't need the radiation to cover their entire mouth. For patients who needed radiation over a huge area (like the whole mouth and throat), the light still helped, but the results were a bit more mixed. It's like using a high-quality sunscreen: it works great on your face, but if you are trying to protect your entire body, you might need a bigger bottle or a different strategy.

The Bottom Line

This study proves that this new "smart mouthguard" is a game-changer. It turns a difficult, labor-intensive medical treatment into something simple that fits right into the daily routine.

In simple terms: If you are fighting cancer with radiation, this device is like giving your mouth a daily "vitamin boost" of healing light. It doesn't stop the cancer, but it stops the treatment from destroying your quality of life, keeping you out of pain, able to eat, and able to finish your therapy without needing extra help. It's a small device with a massive impact on making a tough journey a little less painful.

Technical Summary

1. Problem Statement

Oral Mucositis (OM) is a severe, dose-limiting toxicity affecting over 90% of patients undergoing curative radiation therapy (RT) for head and neck cancer (HNC). It is characterized by inflammation, erythema, and ulceration of the oral mucosa, leading to:

• Severe pain and dysphagia (difficulty swallowing).
• Malnutrition and weight loss.
• Treatment interruptions, unplanned hospitalizations, and increased healthcare costs.
• Reduced quality of life (QoL), including loss of taste and salivary dysfunction.

While clinical guidelines (MASCC/ISOO, WALT) recommend intraoral PBM for OM prevention, widespread adoption is hindered by the logistical burden of current methods. Standard PBM requires trained operators to use handheld probes for 5–10 minutes per day, targeting specific oral sites. This is labor-intensive, prone to variability in dosing, and difficult to standardize across diverse clinical settings. There is a critical need for a standardized, automated, and efficient PBM delivery system.

2. Methodology

Study Design:

• Type: Prospective, multicenter, randomized (1:1), double-blind, sham-controlled clinical trial.
• Registration: NCT03972527.
• Setting: 12 US medical centers.
• Population: 85 patients with squamous cell carcinoma of the oral cavity or oropharynx scheduled for high-dose Intensity-Modulated Radiation Therapy (IMRT) over 6–8 weeks, with or without concurrent chemotherapy.
• Exclusion Criteria: Prior head/neck RT, active OM at baseline, smoking during IMRT, or use of mucositis-preventive medications.

Intervention:

• Device: An intraoral LED-based PBM system (MuReva Phototherapy Inc.) featuring two mouthpieces with silicone-based optical waveguides.
  • Over-tongue mouthpiece: Targets buccal mucosa, tongue, hard/soft palate, and oropharynx.
  • Under-tongue mouthpiece: Targets ventral/lateral tongue, floor of mouth, and submandibular glands.
• Parameters: Wavelength of 660 nm, delivering a nominal dose of 6 J/cm² over a 5-minute cycle per mouthpiece (10 minutes total).
• Protocol: Daily 10-minute treatment immediately prior to each IMRT session.
• Control (Sham): Identical mouthpieces and procedure but with no light emission.
• Blinding: Participants and investigators were blinded; opaque goggles emitting low-intensity red light masked the treatment allocation.

Outcome Measures:

• Primary Endpoint: Oral Mucositis Index (OMI) scores after 6 weeks of RT.
• Secondary Endpoints:
  • Incidence of severe OM (WHO Grade ≥3) during treatment and at 2 weeks post-RT.
  • Duration of severe OM.
  • Patient-Reported Outcomes (PROs): Mouth/throat soreness, throat pain, taste preservation (UoW QoL), and overall OM symptom burden (OMWQ-HN).
  • Medical interventions: Surgical feeding tube placement.
• Safety: Adverse events (AEs) and Unanticipated Adverse Device Effects (UADEs) monitored via NCI CTCAE v5.0.

3. Key Contributions

• Standardization of PBM: This study validates a novel, automated intraoral device that delivers standardized, dose-controlled PBM to the entire oral cavity without the need for manual probe manipulation by operators.
• Workflow Integration: Demonstrates that daily PBM can be seamlessly integrated into the standard radiation therapy workflow (10 minutes pre-RT) with high adherence (99.5% completion rate).
• Subgroup Analysis: Provides granular data on efficacy based on radiation field size, distinguishing between patients receiving subtotal vs. total oral cavity irradiation.
• Comprehensive Efficacy: Moves beyond simple mucosal scoring to include critical functional outcomes like taste preservation and feeding tube dependency.

4. Key Results

Safety and Tolerability:

• The device was safe and well-tolerated. No device-related adverse events were observed.
• Adherence: 99.5% of 2,574 initiated sessions were completed. No procedural modifications were needed for patients with anatomical variations (e.g., edentulism, tongue tie).

Efficacy (Intent-to-Treat Population):

• Severe OM Incidence (WHO Grade ≥3):
  • During 6 weeks of IMRT: Significantly lower in the PBM arm vs. Sham (36.8% vs. 57.1%; p = 0.046).
  • At 2 weeks post-RT: Significantly lower in PBM vs. Sham (10.8% vs. 36.4%; p = 0.042).
  • Overall (Baseline to 2 weeks post-RT): Reduced from 65.7% (Sham) to 42.1% (PBM; p = 0.025).
• Oral Mucositis Index (OMI) Scores:
  • Overall Population: No statistically significant difference in mean OMI scores at 6 weeks (p = 0.338).
  • Subgroup Analysis (Subtotal Irradiation): In patients receiving >30 Gy to <75% of the oral cavity, the PBM arm had significantly lower OMI scores (10.2 vs. 15.3; p = 0.023).
  • Subgroup Analysis (Total Irradiation): No significant difference in patients receiving >75% irradiation, suggesting high-dose fields may attenuate PBM efficacy or require larger sample sizes.

Patient-Reported Outcomes (Per-Protocol Population):

• Soreness: 32% smaller mean increase in mouth/throat soreness in PBM arm (p = 0.029).
• Throat Pain: 28% smaller mean increase in throat pain in PBM arm (p = 0.028).
• Taste Preservation: 35.7% reduction in taste loss in PBM arm compared to Sham (45.9% vs. 71.4%; p = 0.034).
• Symptom Burden: 16.1% reduction in overall OM symptom burden (p = 0.037).

Medical Interventions:

• Feeding Tubes: A 59% reduction in surgical feeding tube placement was observed in the PBM arm (15.2% vs. 37%), though this did not reach statistical significance (p = 0.073).
• Treatment Interruptions: None occurred in either arm.

5. Significance and Conclusion

This trial provides robust evidence that daily intraoral PBM using a standardized LED device is safe, feasible, and effective in reducing the incidence and severity of radiation-induced oral mucositis in HNC patients.

• Clinical Impact: The intervention significantly reduces severe mucositis, preserves taste, and lowers pain scores, directly addressing major barriers to completing curative radiation therapy.
• Implementation: The device overcomes the logistical barriers of traditional PBM (handheld probes), making it viable for routine adoption in both academic and community oncology settings.
• Guideline Alignment: The findings strongly support current MASCC/ISOO and WALT guidelines recommending PBM for OM prevention.
• Future Directions: While effective for subtotal irradiation, the study suggests that patients receiving total oral cavity irradiation may require further investigation or adjusted dosing strategies. The trend toward reduced feeding tube dependency warrants larger studies to confirm statistical significance.

In summary, this study validates a scalable technological solution for a high-burden clinical problem, offering a pathway to improve treatment completion rates and quality of life for head and neck cancer patients.